Intel stock price tumbles 17% on outlook shock — what to watch before Monday’s open
25 January 2026

Intel stock price tumbles 17% on outlook shock — what to watch before Monday’s open

New York, Jan 25, 2026, 05:20 EST — Market closed

Intel (INTC.O) shares ended the day down 17%, closing at $45.07. Roughly 295 million shares traded hands during the session, putting the chipmaker in a tough spot heading into the new week.

The selloff comes at a tricky time for Intel. The stock had been riding a turnaround narrative, but Friday’s drop brought the focus sharply back to fundamentals: can Intel deliver enough product, and can it maintain its margins while doing so.

Late Thursday, Intel projected first-quarter revenue between $11.7 billion and $12.7 billion, falling short of analysts’ $12.51 billion consensus. The chipmaker said it’s struggling to keep up with demand for its AI data center server chips. CEO Lip-Bu Tan told analysts, “In the short term, I’m disappointed that we are not able to fully meet the demand in our markets.” Meanwhile, Running Point Capital CIO Michael Schulman noted Intel’s turnaround “remains supply-constrained rather than demand-constrained.” Reuters

Intel reported fourth-quarter revenue of $13.7 billion, down 4% year-over-year, with a loss of 12 cents per share. On a non-GAAP basis, earnings came in at 15 cents per share. Finance chief David Zinsner noted, “We expect our available supply to be at its lowest level in Q1 before improving in Q2 and beyond.” Intel

Traders will be watching that supply line closely each day next week. Should Intel suggest the shortage persists, investors are likely to see first-quarter guidance as a baseline rather than a temporary hurdle.

Several analysts suggested the pre-earnings surge was fueled more by “the dream” than by immediate facts, pointing out that Intel is already running its factories at full tilt yet still falling short. Jefferies expects the supply crunch to hit bottom in March, while Oppenheimer predicts easing constraints by Q2. The latter also warned of potential headwinds for Intel’s core business, as rising memory prices could dampen PC demand. Reuters

Intel is scrambling to hold its ground against rivals. Nvidia dominates the AI chip space, while AMD continues to push hard in PCs and server processors — crucial markets Intel must defend as it works through supply issues.

The downside is clear. If manufacturing yields—the percentage of usable chips per silicon wafer—don’t get better, or if the PC market weakens beyond forecasts, Intel might miss its targets and see margins squeezed further.

The longer-term story remains critical. Intel’s foundry effort—building chips for outside companies—depends on landing major clients to move from evaluations to actual orders. That transition often takes several quarters before it starts reflecting in the revenue.

Intel filed its results and forward guidance in a Form 8-K with the U.S. Securities and Exchange Commission on Jan. 22.

Trading kicks back in on Monday, Jan. 26, putting the spotlight on fresh analyst revisions following the recent outlook reset. Investors will be watching closely to see if the stock can steady itself after Friday’s drop.

Shan Ahmed Khan

Shan Ahmed Khan is a senior markets reporter at TS2.tech. His coverage ranges from stocks and technology to economic developments across global markets. He worked in investment research and market analysis before becoming a financial journalist and is a graduate of the Lahore University of Management Sciences (LUMS).

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap Holdings

NYSE: AER 92/100
#2 BUY

Uber Technologies

NYSE: UBER 90/100
#3 BUY

Taiwan Semiconductor Manufacturing

NYSE: TSM 89/100
#4 ACCUMULATE

dLocal

NASDAQ: DLO 86/100
#5 ACCUMULATE

Tapestry

NYSE: TPR 84/100
View full portfolio
Editorial model selection. Not personalised advice.
Roche stock price holds near a 52-week high as Jan. 29 results near — what to watch next week
Previous Story

Roche stock price holds near a 52-week high as Jan. 29 results near — what to watch next week

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday
Next Story

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday